NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Novartis · Metastatic Neuroendocrine Prostate Cancer
Phase 1
Active, not recruiting
31
2026-07
Evidence dashboardStudies since 2005Updated Jul 31, 2026
DegarelixClinical Trials.
A source-linked view of every Degarelix study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 75
- Recruiting
- 21
- Completed
- 23
- Terminated
- 2
- Results posted
- 15
- Average enrollment
- 227
- Countries
- 20
- Highest phase
- Phase 4
Largest indexed study
2,753 participants · NCT04513717 →Developer / research origin
Ferring Pharmaceuticals
Evidence summary
Activity is not efficacy.
Degarelix appears in 75 indexed studies: 21 recruiting, 23 completed and 15 with registry results posted. The highest registered development stage in this snapshot is Phase 4. These counts measure registry activity; they do not establish that Degarelix is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
NCT IDStudyPhase / statusEnrollmentUpdated
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Mayo Clinic · Recurrent Castration-Sensitive Prostate Carcinoma · Recurrent Prostate Cancer
Phase 2
Recruiting
532
2026-07
NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial
M.D. Anderson Cancer Center · Prostate Cancer
Phase 1 / Phase 2
Recruiting
6
2026-07
Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)
NYU Langone Health · Intraprostatic Prostate Cancer
Not applicable
Recruiting
28
2026-07
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
University of Wisconsin, Madison · Prostate Cancer
Phase 1 / Phase 2
Active, not recruiting
57
2026-07
Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
Washington University School of Medicine · Prostate Cancer · Cancer of the Prostate
Not applicable
Active, not recruiting
28
2026-07
Showing 6 of 46 studies
NCT IDStudyPhase / statusEnrollmentUpdated
Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center · Prostate Cancer · Prostatic Adenocarcinoma
Not applicable
Completed
41
2026-07
Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy
Memorial Sloan Kettering Cancer Center · Metastatic Castration Sensitive Prostate Cancer
Phase 2
Completed
16
2026-07
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
Stanford University · Prostate Adenocarcinoma · Stage I Prostate Cancer
Not applicable
Completed
146
2026-07
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NRG Oncology · Stage I Prostate Adenocarcinoma AJCC v7 · Stage II Prostate Adenocarcinoma AJCC v7
Phase 2 / Phase 3
Completed
612
2026-06
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Praful Ravi, MB BCHir, MRCP · Metastatic Prostate Cancer · Non-metastatic Prostate Cancer
Phase 1
Completed
9
2026-06
Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer
Assistance Publique - Hôpitaux de Paris · Invasive Ductal Breast Carcinoma
Phase 2
Completed
8
2026-03
Showing 6 of 23 studies
NCT IDStudyPhase / statusEnrollmentUpdated
Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant
Brown University · Urothelial Carcinoma Bladder · Androgen Receptor Positive
Phase 1
Terminated
2
2026-04
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute · High Risk Prostate Carcinoma · Localized Prostate Adenocarcinoma
Phase 2
Withdrawn
0
2025-09
A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer
Memorial Sloan Kettering Cancer Center · Prostate Cancer
Phase 1 / Phase 2
Withdrawn
0
2024-10
Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer
Memorial Sloan Kettering Cancer Center · Prostate Cancer
Phase 3
Terminated
56
2024-08
Full study index
Search Degarelix trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
75 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 34350976 ↗Zengerling F, Jakob JJ, Schmidt S, Meerpohl JJ, Blumle A, Schmucker C, Mayer B, Kunath F. Degarelix for treating advanced hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD012548. doi: 10.1002/14651858.CD012548.pub2.Linked from NCT01542021PMID 41781018 ↗Jarrard D, Eickhoff J, Kyriakopoulos CE, Jeon D, Tonelli TP, Johnson L, Huang W, McNeel DG. Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer. J Immunother Cancer. 2026 Mar 4;14(3):e013790. doi: 10.1136/jitc-2025-013790.Linked from NCT04989946PMID 38421243 ↗Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol. 2024 Apr;211(4):518-525. doi: 10.1097/JU.0000000000003891. Epub 2024 Feb 29.Linked from NCT04423211PMID 40998687 ↗Kleiburg F, Dirix P, Fonteyne V, Bral S, De Troyer B, Sautois B, Lamande M, Liefhooghe N, Grisay G, Meersschout S, Vandermeulen A, Jullian N, Staelens L, Poelaert F, Strijbos M, Verschueren J, Goffin K, Withofs N, Ost P. Stage Migration on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Comparison to Conventional Imaging in Patients with High-risk Prostate Cancer Referred for Radiation Therapy: Results from the Phase 2/3 THUNDER Trial. Eur Urol Oncol. 2025 Oct;8(5):1333-1339. doi: 10.1016/j.euo.2025.08.005. Epub 2025 Sep 25.Linked from NCT06282588PMID 37104748 ↗Krauss DJ, Karrison T, Martinez AA, Morton G, Yan D, Bruner DW, Movsas B, Elshaikh M, Citrin D, Hershatter B, Michalski JM, Efstathiou JA, Currey A, Kavadi VS, Cury FL, Lock M, Raben A, Seaward SA, El-Gayed A, Rodgers JP, Sandler HM. Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial. J Clin Oncol. 2023 Jun 10;41(17):3203-3216. doi: 10.1200/JCO.22.02390. Epub 2023 Apr 27.Linked from NCT00936390PMID 42221687 ↗Moisander M, Holsa O, Teittinen K, Kysenius K, Kosunen M, Lehmus L, Murtola TJ. Characteristics, treatment patterns, and outcomes of patients with metastatic prostate cancer during 2014-2022 in Pirkanmaa, Finland-an observational study. Ther Adv Urol. 2026 May 27;18:17562872261451289. doi: 10.1177/17562872261451289. eCollection 2026 Jan-Dec.Linked from NCT05701007PMID 25559415 ↗Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.Linked from NCT03009981PMID 14665878 ↗Zietman AL, Chung CS, Coen JJ, Shipley WU. 10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. J Urol. 2004 Jan;171(1):210-4. doi: 10.1097/01.ju.0000100980.13364.a6.Linked from NCT03009981
Related pages
Keep researching Degarelix.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.